LABORATORY RESEARCH Cabozantinib Inhibits Abiraterone’s Upregulation of IGF-1R Phosphorylation and Enhances Its Anti-Prostate Cancer Activity Three prostate cancer cell lines were used to interrogate the in vitro molecular and anti-proliferative effects of the single agents and combination of cabozantinib and abiraterone. The in vivo impact of the combination was assessed using the LAPC4-CR xenograft mouse model. [Clin Cancer Res] Abstract Regulation of c-Myc Expression by the Histone Demethylase JMJD1A Is Essential for Prostate Cancer Cell Growth and Survival The authors found that JMJD1A knockdown in prostate cancer cells antagonizes their proliferation and survival. JMJD1A regulated c-Myc stability, likely by inhibiting HUWE1, an E3 ubiquitin ligase known to target degradation of several substrates including c-Myc. [Oncogene] Abstract The Prognostic Significance of CXCL16 and Its Receptor C-X-C Chemokine Receptor 6 in Prostate Cancer Investigators examined how the expression of CXCR16/C-X-C chemokine receptor 6 in prostate cancer was related to clinicopathological features and activation of inflammatory cells. [Am J Pathol] Full Article Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression Scientists demonstrated that ABC294640 abrogates signaling pathways requisite for prostate cancer (PCa) growth and proliferation. Key findings validate that ABC294640 treatment of early stage and advanced PCa models downregulate Myc and AR expression and activity. [Mol Cancer Res] Abstract In Vivo Studies of the PARP Inhibitor, AZD-2281, in Combination with Fractionated Radiotherapy: An Exploration of the Therapeutic Ratio Investigators tested the PARP inhibitor AZD-2281 as a radiosensitizing agent under oxic and hypoxic conditions for clonogenic survival in vitro and in vivo using the human prostate cancer cell line, 22Rv1. [Radiother Oncol] Abstract Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate Researchers report that BE prostate cells have a higher competence to utilize fatty acids as energy source than prostate cancer cells as shown not only by increased cell viability upon fatty acid supplementation but also by an increased ß-oxidation of fatty acids, although the base-line respiration was 2-fold higher in prostate cancer cells. [PLoS One] Full Article CLINICAL RESEARCH Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR-2 as Targets for Growth Inhibition of Prostate Cancer Investigators performed parallel investigations in cabozantinib-treated patients in a Phase II trial and simultaneously in patient-derived xenograft models to better understand the roles of MET and VEGFR-2 as targets for prostate cancer therapy. [Clin Cancer Res] Abstract Dysfunction of PSA-Specific CD8+ T Cells in Prostate Cancer Patients Correlates with CD38 and Tim-3 Expression Researchers assessed the preexisting cellular immunity against prostate-specific antigen in untreated prostate cancer patients and healthy controls through measurement of the phenotype and function of CD8+ T cells. [Cancer Immunol Immunother] Abstract |